{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zajicek F"],"funding":["Universiteit Antwerpen","CHDI Foundation","Research Foundation Flanders"],"pagination":["122-133"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11599348"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["52(1)"],"pubmed_abstract":["<h4>Purpose</h4>Positron emission tomography (PET) imaging of mutant huntingtin (mHTT) aggregates is a potential tool to monitor disease progression as well as the efficacy of candidate therapeutic interventions for Huntington's disease (HD). To date, the focus has been mainly on the investigation of <sup>11</sup>C radioligands; however, favourable <sup>18</sup>F radiotracers will facilitate future clinical translation. This work aimed at characterising the novel [<sup>18</sup>F]CHDI-650 PET radiotracer using a combination of in vivo and in vitro approaches in a mouse model of HD.<h4>Methods</h4>After characterising [<sup>18</sup>F]CHDI-650 using in vitro autoradiography, we assessed in vivo plasma and brain radiotracer stability as well as kinetics through dynamic PET imaging in the heter"],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["Preclinical evaluation of the novel [&lt;sup&gt;18&lt;/sup&gt;F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease."],"pmcid":["PMC11599348"],"funding_grant_id":["1229721N","FFB210050","A-11627"],"pubmed_authors":["Munoz-Sanjuan I","Staelens S","Bertoglio D","Liu L","De Lombaerde S","Verhaeghe J","Van Eetveldt A","Bard J","Dominguez C","Miranda A","Zajicek F","Khetarpal V"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical evaluation of the novel [&lt;sup&gt;18&lt;/sup&gt;F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease.","description":"<h4>Purpose</h4>Positron emission tomography (PET) imaging of mutant huntingtin (mHTT) aggregates is a potential tool to monitor disease progression as well as the efficacy of candidate therapeutic interventions for Huntington's disease (HD). To date, the focus has been mainly on the investigation of <sup>11</sup>C radioligands; however, favourable <sup>18</sup>F radiotracers will facilitate future clinical translation. This work aimed at characterising the novel [<sup>18</sup>F]CHDI-650 PET radiotracer using a combination of in vivo and in vitro approaches in a mouse model of HD.<h4>Methods</h4>After characterising [<sup>18</sup>F]CHDI-650 using in vitro autoradiography, we assessed in vivo plasma and brain radiotracer stability as well as kinetics through dynamic PET imaging in the heter","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-22T14:24:11.324Z","creation":"2025-04-06T01:00:19.722Z"},"accession":"S-EPMC11599348","cross_references":{"pubmed":["39190197"],"doi":["10.1007/s00259-024-06880-x"]}}